This study is looking at a treatment called Cretostimogene for people with a type of bladder cancer known as Non-Muscle Invasive Bladder Cancer (NMIBC) that hasn't responded to a usual treatment called Bacillus-Calmette-Guerin (BCG). The trial is in Phase 3, meaning it's in the final testing stage before it could be approved for general use. Patients are divided into two groups: Cohort C and Cohort P. Cohort C is closed to new patients, while Cohort P is open to about 75 patients in Japan and the United States. To join, you must be at least 18, have specific types of bladder cancer, and can't have had certain other treatments or health problems recently. You also need to agree to regular tests and procedures during the study.

• The study has two groups: Cohort C (closed) and Cohort P (open).
• Participants must have specific bladder cancer unresponsive to BCG.
• Regular tests and procedures are required during the study.